AGA Webcast Series for Advanced Practice Providers – Part I
As part of our ongoing initiative to expand resources for advanced practice providers (APPs), AGA recently launched part one of a two-part IBD pharmacology webcast series for nurse practitioners (NPs). The course offers a comprehensive overview of three of the most widely prescribed pharmacological therapies for IBD including 5-ASA, biologics and immunomodulators. This free resource will assist NPs in meeting their state and national continuing education requirements by providing two pharmacology-specific continuing education credits certified by the American Association of Nurse Practitioners (AANP).
Characterized by chronic inflammation of the intestinal mucosa, IBD constitutes one of the five most prevalent GI disease burdens in the United States (1). Pharmacologic therapies can induce disease remission and improve quality of life for patients. However, treatment is challenging as individuals may become unresponsive to particular drugs or require combination therapy (2,3). A thorough knowledge of inpatient and outpatient management of IBD including drug level and antibody monitoring and long-term side effects is essential for effective treatment.
Survey results from AGA courses indicate over two-thirds of APPs are involved with prescribing drugs for IBD in their practice. Many attendees describe IBD as an area where routine clinical practice should be improved to achieve better patient outcomes. This webcast series offers an in-depth review of three common classes of IBD drugs including their mechanism, side effects, and pharmacokinetics. Case-based examples are included at the end of each module offering insight to those starting in gastroenterology as well as clinical pearls for the experienced APP. The Nurse Practitioner Pharmacology: IBD webcast is sponsored by independent educational grants from Gilead Sciences and Takeda Pharmaceuticals U.S.A., Inc.
A second webcast series is currently being developed. This second series will provide insight on pharmacological management of symptoms related to IBD, corticosteroids and a deeper focus on biologics and JAK inhibitors. We anticipate that these courses will provide the foundation for AGA to continue to build a robust pharmacology resource for APPs.
Companies interested in learning more about this program and for sponsorship opportunities, please contact Sarah Foundas at firstname.lastname@example.org.
1. Hanauer, SB. (2006). Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. Jan;12 Suppl 1:S3-9. Review.
2. Crohn’s & Colitis Foundation (2019). Crohn’s Disease Treatment Options Retrieved from: https://www.crohnscolitisfoundation.org/What-is-crohns-disease/treatment
3. Mosli, Mahmoud, Al Beshir, Mohammad, Al-Judaibi, Bandar et al. (2014). Advances in the Diagnosis and Management of Inflammatory Bowel Disease: Challenges and Uncertainties. Saudi J Gastroenterol. 20(2): 81–101.